Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - A review with Indian perspective

Indian Journal of Medical Research

Volumn 139, Issue , 2014, Pages 27-65

  Umamaheswaran, Gurusamy ^a   Krishna Kumar, Dhakchinamoorthi ^a   Adithan, Chandrasekaran ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Cytochrome P450; Drug metabolizing enzymes; Indians; Pharmacogenetics; Pharmacogenomics; Polymorphism; SNP; Transporters

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLIZING ENZYME; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC CATION TRANSPORTER 1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A2; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; THIOPURINE METHYLTRANSFERASE; ORGANIC ANION TRANSPORTER;

ALLELE; DISEASE PREDISPOSITION; DRUG METABOLISM; DRUG RESPONSE; GENE FREQUENCY; GENE LOCATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; PHARMACOGENOMICS; REVIEW; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG INACTIVATION; GENETICS; INDIA; METABOLISM; PHARMACOGENETICS; POPULATION GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 ENZYME SYSTEM; GENE FREQUENCY; GENETICS, POPULATION; HUMANS; INACTIVATION, METABOLIC; INDIA; ORGANIC ANION TRANSPORTERS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84896850404     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (181)

1. Evans DA, Manley KA, Mc KV. Genetic control of isoniazid metabolism in man. Br Med J 1960; 2:485-91.
2. Chowbay B, Zhou S, Lee EJ. An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters:experience in Singapore. Drug Metab Rev 2005; 37:327-78.
3. Sissung TM, Troutman SM, Campbell TJ, Pressler HM, Sung H, Bates SE, et al. Transporter pharmacogenetics:transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy. Discov Med 2012; 13:19-34.
4. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 2011; 63:437-59.
5. Naveen AT, Adithan C, Padmaja N, Shashindran CH, Abraham BK, Satyanarayanamoorthy K, et al. Glutathione S-transferase M1 and T1 null genotype distribution in South Indians. Eur J Clin Pharmacol 2004; 60:403-6.
6. Soya SS, Padmaja N, Adithan C. Genetic polymorphisms of CYP2E1 and GSTP1 in a South Indian population--comparison with North Indians, Caucasians and Chinese. Asian Pac J Cancer Prev 2005; 6:315-9.
7. Jose R, Chandrasekaran A, Sam SS, Gerard N, Chanolean S, Abraham BK, et al. CYP2C9 and CYP2C19 genetic polymorphisms:frequencies in the south Indian population. Fundam Clin Pharmacol 2005; 19:101-5.
8. Naveen AT, Adithan C, Soya SS, Gerard N, Krishnamoorthy R. CYP2D6 genetic polymorphism in South Indian populations. Biol Pharm Bull 2006; 29:1655-8.
9. Sam SS, Thomas V, Reddy SK, Surianarayanan G, Chandrasekaran A. CYP1A1 polymorphisms and the risk of upper aerodigestive tract cancers in an Indian population. Head Neck 2008; 30:1566-74.
10. Umamaheswaran G, Praveen RG, Arunkumar AS, Das AK, Shewade DG, Adithan C. Genetic analysis of OCT1 gene polymorphisms in an Indian population. Indian J Hum Genet 2011; 17:164-8.
11. Arun Kumar AS, ChakradharaRao US, Umamaheswaran G, Ramu P, Kesavan R, Shewade DG, et al. Haplotype structures of common variants of CYP2C8, CYP2C9, and ADRB1 genes in a South Indian population. Genet Test Mol Biomarkers 2011; 15:407-13.
12. Umamaheswaran G, Krishna Kumar D, Kayathiri D, Rajan S, Shewade DG, Dkhar SA, et al. Inter and intra-ethnic differences in the distribution of the molecular variants of TPMT, UGT1A1 and MDR1 genes in the South Indian population. Mol Biol Rep 2012; 39:6343-51.
13. Krishnakumar D, Gurusamy U, Dhandapani K, Surendiran A, Baghel R, Kukreti R, et al. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population. Fundam Clin Pharmacol 2012; 26:295-306.
14. Anichavezhi D, Chakradhara Rao US, Shewade DG, Krishnamoorthy R, Adithan C. Distribution of CYP2C19*17 allele and genotypes in an Indian population. J Clin Pharm Ther 2012; 37:313-8.
15. Government of India. Census of India. Provisional Population Totals of 2011. Available from:http://www.censusindia.gov.in/2011-prov-results/PPT_2.html, accessed on June 10, 2012.
16. Indian Genome Variation Database. Available from:http://www.igvdb.res.in/references.php, accessed on June 10, 2012.
17. Reich D, Thangaraj K, Patterson N, Price AL, Singh L. Reconstructing Indian population history. Science 2009; 461:489-94.
18. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008; 392:1093-108
19. Sobti RC, Sharma S, Joshi A, Jindal SK, Janmeja A. Genetic polymorphism of the CYP1A1, CYP2E1, GSTM1 and GSTT1 genes and lung cancer susceptibility in a north indian population. Mol Cell Biochem 2004; 266:1-9.
20. Sharma R, Ahuja M, Panda NK, Khullar M. Combined effect of smoking and polymorphisms in tobacco carcinogen-metabolizing enzymes CYP1A1 and GSTM1 on the head and neck cancer risk in North Indians. DNA Cell Biol 2010; 29:441-8.
21. Vibhuti A, Arif E, Mishra A, Deepak D, Singh B, Rahman I, et al. CYP1A1, CYP1A2 and CYBA gene polymorphisms associated with oxidative stress in COPD. Clin Chim Acta 2010; 411:474-80
22. Kumar V, Singh S, Yadav CS, Ahmed RS, Gupta S, Pasha ST, et al. CYP1A1 and CYP3A4 polymorphic variations in Delhi population of Northern India. Environ Toxicol Pharmacol 2010; 29:126-30.
23. Ahmad ST, Arjumand W, Seth A, Nafees S, Rashid S, Ali N, et al. Risk of renal cell carcinoma and polymorphism in phase I xenobiotic metabolizing CYP1A1 and CYP2D6 enzymes. Urol Oncol 2012; 31:1350-7.
24. Singh N, Mitra AK, Garg VK, Agarwal A, Sharma M, Chaturvedi R, et al. Association of CYP1A1 polymorphisms with breast cancer in North Indian women. Oncol Res 2007; 16:587-97.
25. Singh V, Rastogi N, Sinha A, Kumar A, Mathur N, Singh MP. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women. Breast Cancer Res Treat 2007; 101:73-81.
26. Srivastava DS, Mandhani A, Mittal RD. Genetic polymorphisms of cytochrome P450 CYP1A1 (*2A) and microsomal epoxide hydrolase gene, interactions with tobacco-users, and susceptibility to bladder cancer:a study from North India. Arch Toxicol 2008; 82:633-9
27. Anantharaman D, Chaubal PM, Kannan S, Bhisey RA, Mahimkar MB. Susceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1 and GSTT1 loci among Indians:tobacco exposure as a risk modulator. Carcinogenesis 2007; 28:1455-62.
28. Shaffi SM, Shah MA, Bhat IA, Koul P, Ahmad SN, Siddiqi MA. CYP1A1 polymorphisms and risk of lung cancer in the ethnic Kashmiri population. Asian Pac J Cancer Prev 2009; 10:651-6.
29. Malik MA, Upadhyay R, Mittal RD, Zargar SA, Modi DR, Mittal B. Role of xenobiotic-metabolizing enzyme gene polymorphisms and interactions with environmental factors in susceptibility to gastric cancer in Kashmir Valley. J Gastrointest Cancer 2009; 40:26-32.
30. Suryanarayana V, Deenadayal M, Singh L. Association of CYP1A1 gene polymorphism with recurrent pregnancy loss in the South Indian population. Hum Reprod 2004; 19:2648-52.
31. Vani GT, Mukesh N, Siva Prasad B, Rama Devi P, Hema Prasad M, Usha Rani P, et al. Association of CYP1A1*2A polymorphism with male infertility in Indian population. Clin Chim Acta 2009; 410:43-7.
32. Joseph T, Chacko P, Wesley R, Jayaprakash PG, James FV, Pillai MR. Germline genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes in Indian cervical cancer:associations with tumor progression, age and human papillomavirus infection. Gynecol Oncol 2006; 101:411-7.
33. Syamala VS, Syamala V, Sheeja VR, Kuttan R, Balakrishnan R, Ankathil R. Possible risk modification by polymorphisms of estrogen metabolizing genes in familial breast cancer susceptibility in an Indian population. Cancer Invest 2010; 28:304-11.
34. Suneetha KJ, Nancy KN, Rajalekshmy KR, Rama R, Sagar TG, Rajkumar T. Role of glutathione-s-transferase and CYP1A1*2A polymorphisms in the therapy outcome of south Indian acute lymphoblastic leukemia patients. Indian J Med Paediatr Oncol 2011; 32:25-9.
35. Majumdar S, Mondal BC, Ghosh M, Dey S, Mukhopadhyay A, Chandra S, et al. Association of cytochrome P450, glutathione S-transferase and N-acetyl transferase 2 gene polymorphisms with incidence of acute myeloid leukemia. Eur J Cancer Prev 2008; 17:125-32.
36. Ihsan R, Chauhan PS, Mishra AK, Yadav DS, Kaushal M, Sharma JD, et al. Multiple analytical approaches reveal distinct gene-environment interactions in smokers and non smokers in lung cancer. PLoS One 2011; 6:e29431.
37. Parveen F, Faridi RM, Das V, Tripathi G, Agrawal S. Genetic association of phase I and phase II detoxification genes with recurrent miscarriages among North Indian women. Mol Hum Reprod 2010; 16:207-14.
38. Surekha D, Sailaja K, Rao DN, Padma T, Raghunadharao D, Vishnupriya S. Association of CYP1A1*2 polymorphisms with breast cancer risk:a case control study. Indian J Med Sci 2009; 63:13-20.
39. Tiwari AK, Deshpande SN, Rao AR, Bhatia T, Mukit SR, Shriharsh V. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects:I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J 2005; 5:60-9.
40. Singh AP, Pant MC, Ruwali M, Shah PP, Prasad R, Mathur N, et al. Polymorphism in cytochrome P450 1A2 and their interaction with risk factors in determining risk of squamous cell lung carcinoma in men. Cancer Biomark 2010-2011; 8:351-9.
41. Tiwari AK, Deshpande SN, Lerer B, Nimgaonkar VL, Thelma BK. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects:V. Association of CYP1A2 1545 C>T polymorphism. Pharmacogenomics J 2007; 7:305-11.
42. Singh V, Upadhyay G, Rastogi N, Singh K, Singh MP. Polymorphism of xenobiotic-metabolizing genes and breast cancer susceptibility in North Indian women. Genet Test Mol Biomarkers 2011; 15:343-9
43. Ruwali M, Pant MC, Shah PP, Mishra BN, Parmar D. Polymorphism in cytochrome P450 2A6 and glutathione S-transferase P1 modifies head and neck cancer risk and treatment outcome. Mutat Res 2009; 669:36-41.
44. Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 2009; 19:170-9
45. Singh S, Kumar V, Vashisht K, Singh P, Banerjee BD, Rautela R, et al. Role of genetic polymorphisms of CYP1A1, CYP3A5, CYP2C9, CYP2D6, and PON1 in the modulation of DNA damage in workers occupationally exposed to organophosphate pesticides. Toxicol Appl Pharmacol 2011; 257:84-92
46. Yadav SS, Ruwali M, Pant MC, Shukla P, Singh RL, Parmar D. Interaction of drug metabolizing cytochrome P450 2D6 poor metabolizers with cytochrome P450 2C9 and 2C19 genotypes modify the susceptibility to head and neck cancer and treatment response. Mutat Res 2010; 684:49-55.
47. Rathore SS, Agarwal SK, Pande S, Mittal T, Mittal B. Frequencies of VKORC1 -1639 G>A, CYP2C9*2 and CYP2C9*3 genetic variants in the northern Indian population. Biosci Trends 2010; 4:333-7.
48. Paul S, Pant MC, Parmar D, Verma J. Association and treatment response to capecitabine-based chemoradiotherapy with CYP2C9 polymorphism in head and neck cancer. Indian J Cancer 2011; 48:223-9.
49. Lamba JK, Dhiman RK, Kohli KK. CYP2C19 genetic mutations in North Indians. Clin Pharmacol Ther 2000; 68:328-35.
50. Ghodke Y, Joshi K, Arya Y, Radkar A, Chiplunkar A, Shintre P, et al. Genetic polymorphism of CYP2C19 in Maharashtrian population. Eur J Epidemiol 2007; 22:907-15.
51. Siddapuram SP, Banerjee R, Tandan M, Prathap N, Mitnal S, Duvvuru NR. CYP2C19 polymorphism as a predictor of personalized therapy in South Indian population. J Assoc Physicians India 201; 59:490-3.
52. Y adav SS, Ruwali M, Shah PP, Mathur N, Singh RL, Pant MC, et al. Association of poor metabolizers of cytochrome P450 2C19 with head and neck cancer and poor treatment response. Mutat Res 2008; 644:31-7.
53. Singh M, Khanna VK, Shukla R, Parmar D. Association of polymorphism in cytochrome P450 2D6 and N-acetyltransferase-2 with Parkinson's disease. Dis Markers 2010; 28:87-93.
54. Shukla P, Gupta D, Pant MC, Parmar D. CYP2D6 polymorphism:A predictor of susceptibility and chemoradiotherapy in head and neck cancer. J Cancer Res Ther 2012; 8:40-5
55. Soundararajan CC, Adhin A, Tripathi M, Prasad HK, Jain S, Vivekanandhan S. Association of CYP2D6 100 C > T and 2850 C > T polymorphisms with generalized tonic clonic seizures among Indians. J Neural Transm 2006; 113:1873-6.
56. Arif E, Vibhuti A, Alam P, Deepak D, Singh B, Athar M, et al. Association of CYP2E1 and NAT2 gene polymorphisms with chronic obstructive pulmonary disease. Clin Chim Acta 2007; 382:37-42
57. Balaji L, Singh KB, Bhaskar LV. Genetic polymorphisms of the CYP2E1 gene do not contribute to oral cancer susceptibility in south Indians. Asian Pac J Cancer Prev 2011; 12:1523-7.
58. Sameer AS, Nissar S, Qadri Q, Alam S, Baba SM, Siddiqi MA. Role of CYP2E1 genotypes in susceptibility to colorectal cancer in the Kashmiri population. Hum Genomics 2011; 5:530-7.
59. Deka M, Bose M, Baruah B, Bose PD, Medhi S, Bose S, et al. Role of CYP2E1 gene polymorphisms association with hepatitis risk in Northeast India. World J Gastroenterol 2010; 16:4800-8.
60. Rais N, Chawla YK, Kohli KK. CYP3A phenotypes and genotypes in North Indians. Eur J Clin Pharmacol 2006; 62:417-22.
61. Ashavaid T, Raje H, Shalia K, Shah B. Effect of gene polymorphisms on the levels of calcineurin inhibitors in Indian renal transplant recipients. Indian J Nephrol 2010; 20:146-51.
62. Bajpai P, Tripathi AK, Agrawal D. Genetic polymorphism of CYP3A5 in Indian chronic myeloid leukemia patients. Mol Cell Biochem 2010; 336:49-54.
63. Sailaja K, Rao DN, Rao DR, Vishnupriya S. Analysis of CYP3A5*3 and CYP3A5*6 gene polymorphisms in Indian chronic myeloid leukemia patients. Asian Pac J Cancer Prev 2010; 11:781-4.
64. Wojtczak A, Skretkowicz J. Clinical significance of some genetic polymorphisms of cytochromeP-450:family CYP1 and subfamilies CYP2A, CYP2B and CYP2C. Pol Merkur Lekarski 2009; 26:248-52
65. Zhou SF, Wang B, Yang LP, Liu JP. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 2010; 42:268-354.
66. Cypalleles.ki.se. The Human Cytochrome P450 (CYP) Allele Nomenclature Database. Available from:http://www.cypalleles.ki.se/, accessed on June 1, 2012.
67. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001; 10:1239-48.
68. Li Y, Millikan RC, Bell DA, Cui L, Tse CK, Newman B, et al. Cigarette smoking, cytochrome P4501A1 polymorphisms, and breast cancer among African-American and white women. Breast Cancer Res 2004; 6:R460-73.
69. Duell EJ, Holly EA, Bracci PM, Liu M, Wiencke JK, Kelsey KT. A population-based, case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk. J Natl Cancer Inst 2002; 94:297-306.
70. Zhang J, Deng J, Zhang C, Lu Y, Liu L, Wu Q, et al. Association of GSTT1, GSTM1 and CYP1A1 polymorphisms with susceptibility to systemic lupus erythematosus in the Chinese population. Clin Chim Acta 2010; 411:878-81.
71. San Jose C, Cabanillas A, Benitez J, Carrillo JA, Jimenez M, Gervasini G. CYP1A1 gene polymorphisms increase lung cancer risk in a high-incidence region of Spain:a case control study. BMC Cancer 2010; 10:463.
72. Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L, et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression:characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 2003; 64:659-69.
73. Chida M, Yokoi T, Fukui T, Kinoshita M, Yokota J, Kamataki T. Detection of three genetic polymorphisms in the 5'-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res 1999; 90:899-902.
74. Li D, Jiao L, Li Y, Doll MA, Hein DW, Bondy ML, et al. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis 2006; 27:103-11.
75. Di YM, Chow VD, Yang LP, Zhou SF. Structure, function, regulation and polymorphism of human cytochrome P450 2A6.Curr Drug Metab 2009; 10:754-80.
76. Paschke T, Riefler M, Schuler-Metz A, Wolz L, Scherer G, McBride CM, et al. Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method. Toxicology 2001; 168:259-68.
77. Kwon JT, Nakajima M, Chai S, Yom YK, Kim HK, Yamazaki H, et al. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics 2001; 11:317-23.
78. Chen GF, Tang YM, Green B, Lin DX, Guengerich FP, Daly AK, et al. Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method. Pharmacogenetics 1999; 9:327-32.
79. Totah RA, Rettie RE. Cytochrome P450 C8:substrates, inhibitors, pharmacogenetics and clinical relevance. Clin Pharmacol Ther 2005; 77:341-52.
80. Rodenburg EM, Visser LE, Danser AH, Hofman A, van Noord C, Witteman JC, et al. Genetic variance in CYP2C8 and increased risk of myocardial infarction. Pharmacogenet Genomics 2010; 20:426-34.
81. Kudzi W, Dodoo AN, Mills JJ. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet 2009; 10:124.
82. Nakajima M, Fujiki Y, Noda K, Ohtsuka H, Ohkuni H, Kyo S, et al. Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab Dispos 2003; 31:687-90.
83. Pechandova K, Buzkova H, Matouskova O, Perlik F, Slanar O. Genetic polymorphisms of CYP2C8 in the Czech Republic. Genet Test Mol Biomarkers 2012; 16:812-6.
84. Garcia-Martin E, Martinez C, Ladero JM, Agundez JAG. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorhism in healthy individuals. Mol Diag Ther 2006; 10:29-40.
85. Lee C.R., Goldstein J.A., Pieper J.A. Cytochrome P450 2C9 polymorphisms:a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12:251-63.
86. Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19:ethnic variation and clinical significance. Curr Clin Pharmacol 2007; 2:93-109.
87. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010; 11:781-91
88. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F. Validation of methods for CYP2C9 genotyping:frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254:628-31.
89. Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 2001; 51:277-80.
90. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41:913-58.
91. Santos PC, Soares RA, Santos DB, Nascimento RM, Coelho GL, Nicolau JC, et al. CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet 2011; 12:13.
92. Kim KA, Song WK, Kim KR, Park JY. Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles. J Clin Pharm Ther 2010; 35:697-703.
93. Pedersen RS, Brasch-Andersen C, Sim SC, Bergmann TK, Halling J, Petersen MS, et al. Linkage disequilibrium between the CYP2C19*17 allele and wild type CYP2C8 and CYP2C9 alleles:identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol 2010; 66:1199-205.
94. Dandara C, Lombard Z, Du Plooy I, McLellan T, Norris SA, Ramsay M. Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population:a window into diversity. Pharmacogenomics 2011; 12:1663-70.
95. Wang B, Yang LP, Zhang XZ, Huang SQ, Bartlam M, Zhou S. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab Rev 2009; 41:573-643.
96. Teh LK, Bertilsson L. Pharmacogenomics of CYP2D6:molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet 2012; 27:55-67.
97. Zhou Q, Yu XM, Lin HB, Wang L, Yun QZ, Hu SN, et al. Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese. Pharmacogenomics J 2009; 9:380-94.
98. Li GC, Yang J, Zhou T, Chen ZG, Chen W. CYP2D6 genotypes and phenotypes in Chinese Han, Uygur and Kazakh populations. Yao Xue Xue Bao 2011; 46:238-42.
99. Zuo LJ, Guo T, Xia DY, Jia LH. Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations. Genet Test Mol Biomarkers 2012; 16:102-8.
100. Bozina N, Granic P, Lalic Z, Tramisak I, Lovric M, Stavljenic-Rukavina A. Genetic polymorphisms of cytochromes P450:CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat Med J 2003; 44:425-8.
101. Kharash ED, Thummel KE. Identification of cytochrome P4502E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane and methoxyflurane. Anesthesiologist 1993; 79:795-807.
102. Bozina N, Bradamante V, Lovric M. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol 2009; 60:217-42.
103. Lee MY, Mukherjee N, Pakstis AJ, Khaliq S, Mohyuddin A, Mehdi SQ, et al. Global patterns of variation in allele and haplotype frequencies and linkage disequilibrium across the CYP2E1 gene. Pharmacogenomics J 2008; 8:349-56.
104. Wang SM, Zhu AP, Li D, Wang Z, Zhang P, Zhang GL. Frequencies of genotypes and alleles of the functional SNPs in CYP2C19 and CYP2E1 in mainland Chinese Kazakh, Uygur and Han populations. J Hum Genet 2009; 54:372-5.
105. Daly AK. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 2006; 45:13-31.
106. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54:1271-94.
107. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet 2001; 27:383-91
108. Garsa AA, McLeod HL, Marsh S. CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet 2005; 6:19.
109. Liu L, Yang L, Zhang YC, Ai XF, Wang JX, Xiao ZJ. Polymorphisms of drug-metabolizing enzymes genes in a Han Chinese population. Zhonghua Yi Xue Za Zhi 2009; 89:2675-81.
110. Liu CH, Peck K, Huang JD, Lin MS, Wang CH, Hsu WP. Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip. Pharmacogenomics 2005; 6:731-47.
111. Wen S, Wang H, Ding Y, Liang H, Wang S. Screening of 12 SNPs of CYP3A4 in a Chinese population using oligonucleotide microarray. Genet Test 2004; 8:411-6.
112. Oliveira E, Marsh S, van Booven DJ, Amorim A, Prata MJ, McLeod HL. Pharmacogenetically relevant polymorphisms in Portugal. Pharmacogenomics 2007; 8:703-12.
113. Kudzi W, Dodoo AN, Mills JJ. Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population:a plausible explanation for altered metabolism of ivermectin in humans? BMC Med Genet 2010; 11:111.
114. Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy SI, Kishikawa Y, et al. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 2002; 58:417-21.
115. Li D, Zhang GL, Lou YQ, Li Q, Wang X, Bu XY. Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. J Clin Pharm Ther 2007; 32:89-95.
116. Park SY, Kang YS, Jeong MS, Yoon HK, Han KO. Frequencies of CYP3A5 genotypes and haplotypes in a Korean population. J Clin Pharm Ther 2008; 33:61-5.
117. Chou FC, Tzeng SJ, Huang JD. Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab Dispos 2001; 29:1205-9.
118. Jancova P, Anzenbacher P, Anzenbacherova E. Phase II drug metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010; 154:103-16.
119. Singh S, Kumar V, Thakur S, Banerjee BD, Grover SS, Rawat DS. Genetic polymorphism of glutathione S-transferase M1 and T1 in Delhi population of Northern India. Environ Toxicol Pharmacol 2009; 28:25-9.
120. Konwar R, Manchanda PK, Chaudhary P, Nayak VL, Singh V, Bid HK. Glutathione S-transferase (GST) gene variants and risk of benign prostatic hyperplasia:a report in a North Indian population. Asian Pac J Cancer Prev 2010; 11:1067-72.
121. Ruwali M, Singh M, Pant MC, Parmar D. Polymorphism in glutathione S-transferases:susceptibility and treatment outcome for head and neck cancer. Xenobiotica 2011; 41:1122-30.
122. Roy B, Dey B, Chakraborty M, Majumder PP. Frequency of homozygous null mutation at the glutathione-s-transferase M1 locus in some populations of Orissa, India. Anthropol Anz 1998; 56:43-7.
123. Buch SC, Notani PN, Bhisey RA. Polymorphism at GSTM1, GSTM3 and GSTT1 gene loci and susceptibility to oral cancer in an Indian population. Carcinogenesis 2002; 23:803-7.
124. Vettriselvi V, Vijayalakshmi K, Paul SF, Venkatachalam P. Genetic variation of GSTM1, GSTT1 and GSTP1 genes in a South Indian population. Asian Pac J Cancer Prev 2006; 7:325-8.
125. Sreeja L, Syamala V, Hariharan S, Madhavan J, Devan SC, Ankathil R. Possible risk modification by CYP1A1, GSTM1 and GSTT1 gene polymorphisms in lung cancer susceptibility in a South Indian population. J Hum Genet 2005; 50:618-27.
126. Sameer AS, Qadri Q, Siddiqi MA. GSTP1 I105V polymorphism and susceptibility to colorectal cancer in Kashmiri population. DNA Cell Biol 2012; 31:74-9.
127. Mishra DK, Kumar A, Srivastava DS, Mittal RD. Allelic variation of GSTT1, GSTM1 and GSTP1 genes in North Indian population. Asian Pac J Cancer Prev 2004; 5:362-5.
128. Sharma R, Ahuja M, Panda N, Khullar M. Polymorphisms in CYP2A13 and UGT1A7 genes and head and neck cancer susceptibility in North Indians. Oral Dis 2010; 16:760-8.
129. Murugesan R, Vahab SA, Patra S, Rao R, Rao J, Rai P, et al. Thiopurine S-methyltransferase alleles, TPMT*2, *3B and *3C, and genotype frequencies in an Indian population. Exp Ther Med 2010; 1:121-7.
130. Rai PS, Murali TS, Vasudevan TG, Prasada SK, Bhagavath AK, Pai P, et al. Genetic variation in genes involved in folate and drug metabolism in a south Indian population. Indian J Hum Genet 2011; 17:S48-53.
131. Semwal P, Prasad S, Varma PG, Bhagwat AM, Deshpande SN, Thelma BK. Candidate gene polymorphisms among North Indians and their association with schizophrenia in a case-control study. J Genet 2002; 81:65-71.
132. Yadav S, Singhal NK, Singh V, Rastogi N, Srivastava PK, Singh MP. Association of single nucleotide polymorphisms in CYP1B1 and COMT genes with breast cancer susceptibility in Indian women. Dis Markers 2009; 27:203-10.
133. Gupta M, Bhatnagar P, Grover S, Kaur H, Baghel R, Bhasin Y, et al. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 2009; 10:385-97.
134. Anitha A, Banerjee M. Arylamine N-acetyltransferase 2 polymorphism in the ethnic populations of South India. Int J Mol Med 2003; 11:125-31.
135. Singh S, Kumar V, Singh P, Banerjee BD, Rautela RS, Grover SS, et al. Influence of CYP2C9, GSTM1, GSTT1 and NAT2 genetic polymorphisms on DNA damage in workers occupationally exposed to organophosphate pesticides. Mutat Res 2012; 741:101-8.
136. Ginsberg G, Smolenski S, Hattis D, Guyton KZ, Johns DO, Sonawane B. Genetic polymorphism in glutathione transferases (GST):Population distribution of GSTM1, T1, and P1 conjugating activity. J Toxicol Environ Health B Crit Rev 2009; 12:389-439.
137. McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms:cancer incidence and therapy. Oncogene 2006; 25:1639-48.
138. Piacentini S, Polimanti R, Porreca F, Martínez-Labarga C, De Stefano GF, Fuciarelli M. GSTT1 and GSTM1 gene polymorphisms in European and African populations. Mol Biol Rep 2011; 38:1225-30.
139. Sivonova M, Waczulikova I, Dobrota D, Matakova T, Hatok J, Racay P, et al. Polymorphisms of glutathione-S-transferase M1, T1, P1 and the risk of prostate cancer:a case-control study. J Exp Clin Cancer Res 2009; 28:32.
140. Li D, Dandara C, Parker MI. The 341C/T polymorphism in the GSTP1 gene is associated with increased risk of oesophageal cancer. BMC Genet 2010; 11:47.
141. Jiang Y, Li N, Dong P, Zhang N, Sun Y, Han M, et al. Polymorphisms in GSTM1, GSTTI and GSTP1 and nasopharyngeal cancer in the east of China:a case-control study. Asian Pac J Cancer Prev 2011; 12:3097-100.
142. Mackenzie PI, Miners JO, McKinnon RA. Polymorphisms in UDP glucuronosyltransferase genes:functional consequences and clinical relevance. Clin Chem Lab Med 2000; 38:889-92.
143. Schulz C, Boeck S, Heinemann V, Stemmler HJ. UGT1A1 genotyping:a predictor of irinotecan-associated side effects and drug efficacy? Anticancer Drugs 2009; 20:867-79.
144. Ginsberg G, Guyton K, Johns D, Schimek J, Angle K, Sonawane B. Genetic polymorphism in metabolism and host defense enzymes:implications for human health risk assessment. Crit Rev Toxicol 2010; 40:575-619
145. Zheng Z, Park JY, Guillemette C, Schantz SP, Lazarus P. Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk. J Natl Cancer Inst 2001; 93:1411-8.
146. Feng F Y, Liang G, Lu WF, Miao XP, Yu CY, Tan W, et al. Correlation of polymorphisms of UDP-glucuronosyltransferase 1A7 gene to genetic susceptibility of lung cancer. Ai Zheng 2005; 24:1085-90.
147. Piepoli A, Gentile A, Valvano MR, Barana D, Oliani C, Cotugno R, et al. Lack of association between UGT1A7, UGT1A9, ARP, SPINK1 and CFTR gene polymorphisms and pancreatic cancer in Italian patients. World J Gastroenterol 2006; 12:6343-8.
148. Lankisch T. O, Vogel A, Eilermann S, Fiebeler A, Krone B, Barut A, et al. Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene. Mol Pharmacol 2005; 67:1732-9.
149. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008; 64:753-67.
150. Lindsay J, Wang LL, Li Y, Zhou SF. Structure, function and polymorphism of human cytosolic sulfotransferases. Curr Drug Metab 2008; 9:99-105.
151. Hebbring SJ, Moyer AM, Weinshilboum RM. Sulfotransferase gene copy number variation:pharmacogenetics and function. Cytogenet Genome Res 2008; 123:205-10.
152. Nowell S, Ratnasinghe DL, Ambrosone CB, Williams S, Teague-Ross T, Trimble L, et al. Association of SULT1A1 phenotype and genotype with prostate cancer risk in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 2004; 13:270-6.
153. Liang G, Miao X, Zhou Y, Tan W, Lin D. A functional polymorphism in the SULT1A1 gene (G638A) is associated with risk of lung cancer in relation to tobacco smoking. Carcinogenesis 2004; 25:773-8.
154. Tunbridge EM. The catechol-O-methyltransferase gene:its regulation and polymorphisms. Int Rev Neurobiol 2010; 95:7-27.
155. Gupta M, Kaur H, Jajodia A, Jain S, Satyamoorthy K, Mukerji M, et al. Diverse facets of COMT:from a plausible predictive marker to a potential drug target for schizophrenia. Curr Mol Med 2011; 11:732-43.
156. Le Marchand L, Donlon T, Kolonel LN, Henderson BE, Wilkens LR. Estrogen metabolism-related genes and breast cancer risk:the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2005; 14:1998-2003.
157. Wen W, Cai Q, Shu XO, Cheng JR, Parl F, Pierce L, et al. Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and breast cancer risk in Chinese women:results from the shanghai breast cancer study and a meta-analysis. Cancer Epidemiol Biomarkers Prev 2005; 14:329-35.
158. Van Esch A A, de Vries E, Te Morsche RH, van Oijen MG, Jansen JB, Drenth JP. Catechol-O-methyltransferase (COMT) gene variants and pain in chronic pancreatitis. Neth J Med 2011; 69:330-4.
159. Vargas-Alarcon G, Fragoso JM, Cruz-Robles D, Vargas A, Vargas A, Lao-Villadoniga J et al. Catechol-O-methyltransferase gene haplotypes in Mexican and Spanish patients with fibromyalgia. Arthritis Res Ther 2007; 9:R110.
160. Hein DW. Molecular genetics and function of NAT1 and NAT2:role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002; 506-507:65-77.
161. García-Martín E. Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Curr Drug Metab 2008; 9:487-97.
162. Sharom FJ. ABC multidrug transporters:structure, function and role in chemo resistance. Pharmacogenomics 2008; 9:105-27.
163. Choi MK, Song IS. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet 2008; 23:243-53.
164. Poduri A, Khullar M, Bahl A, Sharma YP, Talwar KK. A combination of proatherogenic single-nucleotide polymorphisms is associated with increased risk of coronary artery disease and myocardial infarction in Asian Indians. DNA Cell Biol 2009; 28:451-60.
165. Grover S, Bala K, Sharma S, Gourie-Devi M, Baghel R, Kaur H, et al. Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients. Biochimie 2010; 92:1207-12.
166. Jafar T, Prasad N, Agarwal V, Mahdi A, Gupta A, Sharma R, et al. MDR-1 gene polymorphisms in steroid-responsive versus steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 2011; 26:3968-74.
167. Ghodke Y, Chopra A, Shintre P, Puranik A, Joshi K, Patwardhan B. Profiling single nucleotide polymorphisms (SNPs) across intracellular folate metabolic pathway in healthy Indians. Indian J Med Res 2011; 133:274-9.
168. Rao DN, Anuradha C, Vishnupriya S, Sailaja K, Surekha D, Raghunadharao D, et al. Association of an MDR1 gene (C3435T) polymorphism with acute leukemia in India. Asian Pac J Cancer Prev 2010; 11:1063-6.
169. Jindal C, Kumar S, Choudhari G, Goel H, Mittal B. Organic anion transporter protein (OATP1B1) encoded by SLCO1B1 gene polymorphism (388A>G) & susceptibility in gallstone disease. Indian J Med Res 2009; 129:170-5.
170. Srivastava A, Srivastava A, Srivastava N, Choudhuri G, Mittal B. Organic anion transporter 1B1 (SLCO1B1) polymorphism and gallstone formation:High incidence of Exon4 CA genotype in female patients in North India. Hepatol Res 2011; 41:71-8.
171. Cascorbi I. P-glycoprotein:tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 2011; 201:261-83.
172. Allabi AC, Horsmans Y, Issaoui B, Gala JLSingle nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population. Eur J Clin Pharmacol 2005; 61:97-102.
173. Xu P, Jiang ZP, Zhang BK, Tu JY, Li HD. Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers. Pharmacology 2008; 82:221-7.
174. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69:169-74.
175. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters:structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007; 24:1227-51.
176. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011; 50:81-98.
177. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008; 83:258-64.
178. Becker ML, Visser LE, van Shaik RH, Hofman A, Uitterlinden AG, Stricker BH. OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics 2011; 12:79-82.
179. Takane H. Genetic polymorphisms of SLCO1B1 for drug pharmacokinetics and its clinical implications. Yakugaku Zasshi 2011; 131:1589-94.
180. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158:693-705.
181. Aklillu E, Mugusi S, Ngaimisi E, Hoffmann MM, Konig S, Ziesenitz V, et al. Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method. Eur J Clin Pharmacol 2011; 67:1139-45.